Vildagliptin MS, Metformin HCl

Description

Introducing Vildagliptin MS, Metformin HCl Tablets by PharmAlliance International Labs

At PharmAlliance International Labs, we embark on a mission to redefine healthcare by introducing innovative pharmaceutical solutions. Our latest breakthrough, Vildagliptin MS, Metformin HCl Tablets, epitomizes our unwavering commitment to offering effective treatments for metabolic disorders.

Drug Classification: Advancing Diabetes Management with Antidiabetic Agents

Vildagliptin and Metformin Hydrochloride (HCl) tablets belong to the esteemed class of antidiabetic agents. Vildagliptin operates as a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Metformin functions as a biguanide. This synergistic combination aids in enhancing glycemic control among patients grappling with type 2 diabetes mellitus.

Formulations: Tailored Solutions for Optimal Treatment

Our Vildagliptin MS, Metformin HCl Tablets come in two potent formulations:

Vildagliptin 50 mg / Metformin HCl 850 mg Tablets (14’s)

Vildagliptin 50 mg / Metformin HCl 1000 mg Tablets (14’s)

These oral tablets offer convenient administration, packaged meticulously in blister packs containing 14 tablets each for easy handling and storage.

Indications: Managing Type 2 Diabetes Mellitus with Precision

Vildagliptin MS, Metformin HCl Tablets are specifically indicated for adults grappling with type 2 diabetes mellitus. This dynamic combination medication facilitates blood sugar regulation by enhancing insulin secretion and sensitivity, thereby fostering glycemic control.

Usage: Optimizing Treatment Efficacy

To optimize treatment outcomes, it is imperative to administer Vildagliptin MS, Metformin HCl Tablets orally with meals. This practice helps mitigate the risk of gastrointestinal side effects commonly associated with Metformin. Adherence to the prescribed dosage and regimen outlined by healthcare providers is paramount, with regular blood glucose monitoring necessary to evaluate treatment efficacy and facilitate dosage adjustments as warranted.

Dosage: Tailoring Treatment to Individual Needs

The dosage of Vildagliptin MS, Metformin HCl Tablets may vary based on individual response to treatment and glycemic control objectives. Typically, treatment commences with one tablet taken twice daily, with gradual titration guided by blood glucose levels and tolerance. Dosage adjustments may be warranted in patients with renal impairment or concurrent comorbidities.

Pharmacokinetics and Pharmacodynamics: Understanding Mechanisms of Action

Vildagliptin exhibits rapid absorption post-oral administration, with peak plasma concentrations achieved within 1-4 hours. Similarly, Metformin is swiftly absorbed, reaching peak plasma concentrations within 2-3 hours. Renal elimination predominates for both Vildagliptin and Metformin, with Metformin primarily excreted unchanged in the urine. Mechanistically, Vildagliptin inhibits the enzyme DPP-4, thereby prolonging the action of incretin hormones like GLP-1 and GIP, leading to enhanced insulin secretion and diminished glucagon release. Metformin primarily acts by curbing hepatic glucose production and augmenting peripheral glucose uptake, culminating in reduced blood glucose levels.

Side Effects: Prioritizing Patient Safety

While Vildagliptin MS, Metformin HCl Tablets are generally well-tolerated, some individuals may experience gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal discomfort. Rare but severe side effects, including lactic acidosis, may occur, particularly in patients with renal impairment or predisposing factors. Promptly notify healthcare providers of any persistent or severe side effects for appropriate management.

Experience the efficacy and safety of Vildagliptin MS, Metformin HCl Tablets from PharmAlliance International Labs. Place your trust in our unwavering commitment to delivering quality medications that enhance the lives of patients grappling with type 2 diabetes mellitus. For further details, visit our website or consult your healthcare provider today.